Lantheus (NASDAQ:LNTH) Releases FY 2026 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 5.000-5.250 for the period, compared to the consensus estimate of 4.990. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Lantheus Stock Performance

LNTH traded up $2.06 on Friday, hitting $93.06. The company’s stock had a trading volume of 1,540,225 shares, compared to its average volume of 926,525. The company’s 50 day simple moving average is $79.69 and its 200-day simple moving average is $68.87. The firm has a market cap of $6.06 billion, a P/E ratio of 27.61 and a beta of -0.08. Lantheus has a 12 month low of $47.25 and a 12 month high of $94.86. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period last year, the firm earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts forecast that Lantheus will post 4.26 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on LNTH shares. Wall Street Zen raised shares of Lantheus from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 28th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Friday. Truist Financial increased their target price on shares of Lantheus from $89.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Mizuho increased their target price on shares of Lantheus from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus price target of $97.29.

Lantheus News Summary

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Lantheus reported first-quarter EPS of $1.46, beating estimates of $1.25, on revenue of $377.3 million, also above expectations. The beat suggests solid underlying demand and execution. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: The company issued FY2026 EPS guidance of $5.00 to $5.25, slightly above the consensus estimate, reinforcing expectations for continued profitability. Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Citizens JMP raised its price target to $115 from $85 and reiterated a Market Outperform rating, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Mizuho also lifted its price target to $100 from $95 and kept an Outperform rating, adding to the bullish post-earnings analyst momentum. Benzinga
• Neutral Sentiment: Several follow-up stories highlighted valuation and the earnings call transcript, but these were mainly commentary on the already-reported results rather than new catalysts. Lantheus Holdings (LNTH) Valuation Check After Q1 Earnings Beat And FDA Approval Catalysts

Institutional Trading of Lantheus

Several institutional investors and hedge funds have recently bought and sold shares of LNTH. Smartleaf Asset Management LLC raised its position in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the 2nd quarter valued at $36,000. Parallel Advisors LLC raised its position in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Lantheus during the 4th quarter valued at $39,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lantheus during the 3rd quarter valued at $55,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.